We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-1.57%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.47B
AUM Growth
-$458M
Cap. Flow
+$15.5M
Cap. Flow %
0.35%
Top 10 Hldgs %
43.81%
Holding
163
New
19
Increased
16
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$65.4M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$64M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$58.4M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$56.3M
5
OMGA
Omega Therapeutics, Inc. Common Stock
OMGA
+$43.6M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$65.4M
2
XLRN
Acceleron Pharma
XLRN
+$52.3M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$38.8M
4
SEER icon
Seer Inc
SEER
+$28.8M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$24.3M

Sector Composition

Rank Sector Weight
1 Healthcare 82%
2 Consumer Discretionary 6.51%
3 Financials 0.67%
4 Consumer Staples 0.51%
5 Materials 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNS
76
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$11.4M 0.25%
1,000,000
– –
NBTX
77
Nanobiotix
NBTX
$1.88B
$11.4M 0.25%
1,000,000
– –
MRSN
78
DELISTED
Mersana Therapeutics
MRSN
$11.3M 0.25%
48,000
– –
LYEL icon
79
Lyell Immunopharma
LYEL
$323M
$10.4M 0.23%
35,000
– –
BPMC
80
DELISTED
Blueprint Medicines
BPMC
$10.3M 0.23%
100,000
– –
CRIS icon
81
Curis
CRIS
$9.67M
$10.2M 0.23%
3,250
– –
CRBU icon
82
Caribou Biosciences
CRBU
$147M
$9.68M 0.22%
+405,347
New +$9.91M
SPRO icon
83
Spero Therapeutics
SPRO
$68.9M
$9.21M 0.21%
500,000
– –
SANA icon
84
Sana Biotechnology
SANA
$860M
$9.01M 0.2%
400,000
– –
SYRS
85
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$8.94M 0.2%
200,000
+30,000
+18% +$1.46M
VOR icon
86
Vor Biopharma
VOR
$1.06B
$8.62M 0.19%
27,500
– –
CYCN icon
87
Cyclerion Therapeutics
CYCN
$14.9M
$8.53M 0.19%
138,956
– –
DYN icon
88
Dyne Therapeutics
DYN
$4.2B
$8.53M 0.19%
525,000
– –
OVID icon
89
Ovid Therapeutics
OVID
$427M
$8.4M 0.19%
2,500,000
– –
ORIC icon
90
Oric Pharmaceuticals
ORIC
$1.16B
$8.36M 0.19%
400,000
– –
SYRE icon
91
Spyre Therapeutics
SYRE
$8.36B
$8.31M 0.19%
41,800
– –
TIL icon
92
Instil Bio
TIL
$49.2M
$8.04M 0.18%
22,500
– –
IQ icon
93
iQIYI
IQ
$1.2B
$8.03M 0.18%
1,000,000
– –
HARP
94
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$7.9M 0.18%
100,000
– –
IMCR icon
95
Immunocore
IMCR
$1.69B
$7.41M 0.17%
200,000
– –
OMEG
96
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$7.3M 0.16%
750,000
– –
OLMA icon
97
Olema Pharmaceuticals
OLMA
$991M
$7.18M 0.16%
260,500
– –
SLDB icon
98
Solid Biosciences
SLDB
$795M
$7.17M 0.16%
200,000
+50,000
+33% +$2.12M
EVLO
99
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$7.04M 0.16%
50,000
– –
ACIU icon
100
AC Immune
ACIU
$231M
$6.71M 0.15%
1,000,000
– –
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2021 Portfolio in Review

As of Q3 2021, Artal Group held 163 positions worth $4.47B, down 9.3% from $4.93B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Artal Group's Q3 2021 filing shows 19 new, 16 increased, 16 reduced and 17 closed positions. Its largest new stake was Erasca: 3,172,221 shares worth $67.3M. The largest sale was BeOne Medicines Ltd, an estimated $65.4M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 74% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Artal Group's largest Q3 2021 buy was Erasca: 3,172,221 shares worth $67.3M.
  • Artal Group added most to Mirati Therapeutics, Inc. Common Stock in Q3 2021, an estimated $56.3M increase.
  • Artal Group's biggest Q3 2021 reduction was BeOne Medicines Ltd, cutting an estimated $65.4M.
  • Artal Group fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q3 2021, selling an estimated $38.8M.
  • Artal Group's ten largest holdings make up 44% of its $4.47B portfolio in Q3 2021.
  • Artal Group opened 19 new positions and closed 17 in Q3 2021.
  • Artal Group's portfolio value fell 9.3% quarter-over-quarter to $4.47B.

Based on Artal Group's 13F filing for Q3 2021, filed 12 Nov 2021.